Replies to post #140099 on Bioelectronics Corp (BIEL)

[markjohn62]

Sweet. Can you ask him about Allay? What is the path forward on that? New 510k? Would they want to partner it? What is the path forward on migraine Tx? Thank for making the trip CCS.

[uksausage]

Good job, I think we need an explanation of why Boots.com doesn’t even mention the product. It’s been 6 weeks I think. Used to be bae to check in store stock. No mention of restricted supply and prescription only or anything, just disappeared. Poof.

I would discuss their manufacturing capacity and how to decide who gets what when in short supply! Nice problem for them

[srinsocal]

Thanks for sharing CCS, I think that we saw the shift to a Partnership model in Q1 2018. The drastic reduction in Advertising Expense was a good indicator that they no longer felt spending $130k a Quarter was giving an acceptable ROI.

Q1 would have been the time frame of high interest from Bayer and most likely several other potential Partners due to the NHS news. Why go in further debt for millions to finance a Consumer Education/Marketing Campaign when partnering with a multi billion dollar Big Pharma Company can give you instant credibility/notoriety??

Similar model with the NHS. The NHS has run deficits for years and they either need to cut costs or raise taxes. BIEL showed them how they can cut costs and improve the quality of life for chronic pain patients. Win/Win for BIEL and NHS. The NHS promotes ActiPatch internally, ActiPatch saves the money that a UK marketing campaign would cost and gets the association with a Healthcare Icon.

Just selling the IP would be another step down that road and it makes a lot of sense. Fund your R and D, keep cranking out the new indications, let Big Pharma manufacture and market while you cash a royalty check every month.

I wish you an enjoyable trip to Frederick!

[Rheeper]

I’m sure you have some great questions prepared. If you need additional questions to ask Andy / Keith, here are some suggestions:

*Sales*
1) Do you have sufficient manufacturing capacity to meet a surge in demand. What is current capacity utilization. If current utilization is high, do they need to add (e.g., spend money) capacity?
2) Is this an order based business? If yes, can they share or quantify order outlook. What’s current order backlog?
3) To the extent that they can share, can you provide rough sales contribution from NHS, Dr. Scholls, B Braun.
4) Any update on US retail penetration. Would near-term FDA approval help? Andy has downplayed this in the past.

*BOD*
1) who is on the board of directors. Who is chairman

*Share structure*
1) can they break down insider ownership.
2) what are their thoughts on current share count vis a vis A/S. Given the pace of conversion of CBs is there a possibility of another increase in A/S by year end?